Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Koenecke

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Nature Immunology|April 11, 2018
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cellsQuirin Hammer, Timo Rückert, Eva Maria Borst, et al.
Blood Advances|January 6, 2023
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Claudia Rossig, Martin Hutter, et al.
Journal for Immunotherapy of Cancer|April 18, 2023
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Bone Marrow Transplantation|August 12, 2023
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party studyTapani Ruutu, Christophe Peczynski, Mohamed Houhou, et al.
Hemasphere|October 6, 2023
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated PatientsVictoria Panagiota, Johanna Franziska Kerschbaum, Olaf Penack, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2017
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell TransplantationNicolaus Kröger, Victoria Panagiota, Anita Badbaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.
Nature Medicine|October 23, 2023
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialAndreas Mackensen, John B A G Haanen, Christian Koenecke, et al.
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Nature Immunology|April 11, 2018
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cellsQuirin Hammer, Timo Rückert, Eva Maria Borst, et al.
Blood Advances|January 6, 2023
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Claudia Rossig, Martin Hutter, et al.
Journal for Immunotherapy of Cancer|April 18, 2023
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Bone Marrow Transplantation|August 12, 2023
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party studyTapani Ruutu, Christophe Peczynski, Mohamed Houhou, et al.
Hemasphere|October 6, 2023
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated PatientsVictoria Panagiota, Johanna Franziska Kerschbaum, Olaf Penack, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2017
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell TransplantationNicolaus Kröger, Victoria Panagiota, Anita Badbaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.
Nature Medicine|October 23, 2023
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialAndreas Mackensen, John B A G Haanen, Christian Koenecke, et al.
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Pageof 11